The Most Elaborate Perpetual Pump'n'Dump In Need of Shorting

Tin foil hat level of conspiracy posting so I will put a few simple points to counter your unfounded claims: (I have a massive long position on this so of course I'm inclined to be positive) 1. WT1 is rare: Absolutely not, it is over expressed in more than 90% of AML patients, basically a nearly universal marker for that cancer. This means your reduced revenue math based on the tiny "1%" slice is flat wrong.  2. Keytruda comparison: GPS is a cancer vaccine while Keytruda is a checkpoint inhibitor, so while it's not exactly the same but if GPS works it will be the standard of care in a market without many options, so even a modest $500M revenue would justify a significantly higher valuation than what it's at now. 3. Death statistics: IDMC response suggests otherwise from your "drug isn't working" claim. IDMC has reviewed the unblinded data regularly and repeatedly recommended the trial to continue without modification, so if GPS had failed to beat the BAT arm significantly or there's not enough of a split between the two, the trial would've stopped for futility long ago, no matter how much better BAT has gotten.  4. Survivor bias: Phase 3 trials are randomized and in this case, "Healthier groups" and the "Less healthy" ones are distributed equally between the 2 arms by a computer, so the statistical power is supposed to file out the random chance that you described.  I agree on not being overly positive on the drug trial like all biotech bets, like your points on possible dilution and study delays being possibly positive or negative. But please educate yourself and find out the facts and factors behind the trial before snorting more Elon bs ✌️